Boston Life Sciences To Present At The Parkinson's Action Network (PAN) Research And Education & Public Policy Forum

Published: Feb 16, 2006

HOPKINTON, Mass., Feb. 16 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. today announced that Dr. Mark Hurtt, Chief Medical Officer of Boston Life Sciences, Inc., will be speaking in a forum session called "Emerging Therapies: Parkinson's Treatments in the Pipeline" at the Parkinson's Action Network (PAN) Research and Education & Public Policy Forum on Monday, February 20, 2006. The conference is being held February 19 - 21, 2006 at the Holiday Inn on the Hill in Washington D.C.

The Parkinson's Action Network is the leading advocacy voice of the Parkinson's community. It strives to increase awareness about Parkinson's disease and accelerate federal support for Parkinson's research.

Dr. Hurtt's presentation will be webcast on the PAN website. To sign up and view this webcast, please register at the following address: http://www.vodium.com/goto/pan/apokyn.asp.

About Boston Life Sciences, Inc.

Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and a Phase II clinical trial for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of stroke, O-1369 for the treatment of Parkinson's disease and FLUORATEC(TM), a second generation molecular imaging agent, for PS and ADHD. BLSI's current research collaborations include Harvard Medical School, Children's Hospital of Boston and the University of Massachusetts-Worcester.

ALTROPANE is a registered trademark of Boston Life Sciences, Inc.

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future, including the Company's development efforts regarding the Company's ALTROPANE program and the Company's pre-clinical candidates. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on form 10-Q for the quarter ended September 30, 2005, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Boston Life Sciences, Inc. is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Contact: Sharon Correia -- 508-497-2360 ext 224 Boston Life Sciences, Inc. scorreia@bostonlifesciences.com

Boston Life Sciences, Inc.

CONTACT: Sharon Correia of Boston Life Sciences, Inc., +1-508-497-2360 ext224, scorreia@bostonlifesciences.com

Back to news